Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial

Eur Respir J. 2020 May 27;55(5):1902370. doi: 10.1183/13993003.02370-2019. Print 2020 May.

Authors

Souheil El-Chemaly^{1

2}, Angelo Taveira-DaSilva³, Shefali Bagwe¹, Katarzyna Klonowska¹, Tania Machado³, Anthony M Lamattina¹, Hilary J Goldberg¹, Amanda M Jones³, Patricia Julien-Williams³, Rie Maurer⁴, Ivan O Rosas^{1

5}, Elizabeth P Henske¹, Joel Moss³, David J Kwiatkowski^{1

2}

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Equal contribution.
³ Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
⁴ The Harvard Clinical and Translational Science Center, Boston, MA, USA.
⁵ Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA.

PMID: 32060062
DOI: 10.1183/13993003.02370-2019

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Adult
Celecoxib / administration & dosage*
Celecoxib / adverse effects
Cyclooxygenase 2 Inhibitors / administration & dosage*
Cyclooxygenase 2 Inhibitors / adverse effects
Female
Humans
Lymphangioleiomyomatosis / drug therapy*
Male
Middle Aged
Respiratory Function Tests

Substances

Cyclooxygenase 2 Inhibitors
Celecoxib

Associated data

ClinicalTrials.gov/NCT02484664